Sanofi Delay Boosts Novo's Bid For Insulin Dominance

 
• By The Pink Sheet Daily

The delay to Sanofi's insulin/GLP-1 combo may help Novo push Lantus off the top-spot.

More from Archive

More from Pink Sheet